Daily Oral Paltusotine Maintains Acromegaly Treatment Benefit in Phase 3 Trial
Crinetics announced findings from the PATHFNDR-1 trial showing the investigative oral daily drug may provide patients with the rare disease an alternative from recurring injection therapy.
Source: ajmc.com